SPRY EBITDA Growth
Ars Pharmaceuticals Inc · EBITDA Growth
SPRY EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-340.53%period ending
SPRY TTM EBITDA YoY % (39.76% → -340.53%)
Year-over-year change
High-resolution chart · PNG
SPRY ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -340.5312% | |
| -1,191.0312% | |
| -2,078.4554% | |
| -56.3619% | |
| -4.9375% | |
| 70.0093% | |
| 115.645% | |
| 20.323% | |
| 15.9566% | |
| -18.5553% | |
| -59.1068% | |
| -152.0722% | |
| -130.5482% | |
| -96.236% | |
| -88.4624% | |
| 6.1424% | |
| 13.7874% | |
| 22.4053% | |
| 39.7611% |